Navigation Links
U.S. Court of Appeals Upholds Validity of Lilly's Alimta Compound Patent
Date:8/24/2012

INDIANAPOLIS, Aug. 24, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Court of Appeals for the Federal Circuit has affirmed a prior ruling by the U.S. District Court for the District of Delaware that the company's compound patent for Alimta® (pemetrexed) is valid. The compound patent provides protection for Alimta in the U.S. through January of 2017.

"We are pleased with today's ruling from the Court of Appeals affirming the validity of the compound patent for Alimta," said Robert A. Armitage, senior vice president and general counsel for Lilly. "By affirming the district court ruling, we believe that the Court fairly applied long-standing patent law principles. Protection of intellectual property rights is extremely important to the biopharmaceutical industry and the physicians and patients we serve, as these rights help support the development of the next generation of innovative medicines to treat unmet medical needs."

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers – through medicines and information – for some of the world's most urgent medical needs.  Additional information about Lilly is available at www.lilly.com.  C-LLY

This release contains forward-looking statements regarding the U.S. Alimta patent litigation. These statements are based on management's current expectations but actual results may differ materially.  There can be no assurance that the company will prevail in any appeal.  Also, the company cannot predict with certainty whether generic pemetrexed will be marketed prior to the expiration of exclusivity based on the compound patent.  Other risk factors that may affect the company's results can be found in the company's latest Forms 10-K and 10-Q filed with the U.S. Securities and Exchange Commission.

Alimta ® (pemetrexed, Lilly)

(Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO)

 


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Court Preliminarily Deems Millennium Laboratories Press Release Misleading
2. Lilly Statement on Affordable Care Act Ruling by Supreme Court
3. Response to U.S. Supreme Courts Healthcare Decision by Michael Zamagias, Chairman, TeleTracking Technologies
4. Attorneys for Class of Female VPs and SVPs Employed by PR Giant MSLGroup Clarify Companys Inaccurate Description of Federal Courts Recent Certification Ruling
5. Berger & Montague, P.C. Reminds Viropharma Shareholders That The Deadline To Petition The Court To Act As Lead Plaintiff Is July 23, 2012
6. Judge Upholds $3.3 Million Judgment In Favor of Fox Insurance Company Against Former Pharmacy Benefit Manager
7. Data from Study of Elderly Depressed Patients are Reported for Investigational Compound Lu AA21004 on Symptoms of Major Depressive Disorder (MDD)
8. CutisPharma Homogeneity and Stability Study for Mouthwash Compounding Kits Presented at NERDG Meeting
9. Essential Medical Dismisses Patent Case against Masimo and Cercacor
10. Ampio Awarded US and Canadian Patents that will Bolster the Commercialization of Optina™ for the treatment of Diabetic Macular Edema (DME)
11. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... NEW YORK , April 28, 2016 /PRNewswire/ ... will notably complement the company,s valve repair and ... the move also places Abbott more firmly into ... one of the fastest growing device areas, with ... to its recent report,  Advanced Remote Patient ...
(Date:4/28/2016)...  Marking its one year anniversary since launching ... risk test, Color Genomics announced a ... impact the most common hereditary cancers affecting both ... analyzes hereditary cancer risks for breast, colorectal, melanoma, ... Color Test is physician ordered and includes genetic ...
(Date:4/28/2016)... -- The blood testing market in China ... and The Freedonia Group in a recent report.  The ... healthcare research firm said that China ... and in improving testing at the provincial level.   The ... Blood Testing Market in China , which utilized ...
Breaking Medicine Technology:
(Date:4/29/2016)... Springs, California (PRWEB) , ... April 29, 2016 ... ... lies at the heart of our nation’s productivity, stability, even security. Most importantly, ... for their organizations. , Then why are American workers so unhappy? , Just ...
(Date:4/29/2016)... ... ... Conditions were ideal for Global Lyme Alliance’s (GLA) 2nd annual “Bite Back Against ... breeze and temperatures in the 60s. Over 400 runners, walkers and volunteers participated in ... 1-mile walk were held to increase awareness about Lyme disease and to raise funds ...
(Date:4/29/2016)... , ... April 29, 2016 , ... Spine Team Texas, ... is proud to announce one of their physicians has been invited to be a ... (Texas ACOFP) Family Practice Review conference on April 30, 2016. , Dr. R. ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... announces the Gyrociser, an exercise invention which aids in proper muscle development. , ... Cooper, CEO and Creative Director of World Patent Marketing. "Globalization has threatened the ...
(Date:4/29/2016)... ... April 29, 2016 , ... Dr. Robert Mondavi, one ... to improve smiles. Cosmetic dentistry is a fast-growing field as more patients are discovering ... patients to learn more about the options currently available to them and which ones ...
Breaking Medicine News(10 mins):